Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinoma
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
This is a prospective open label clinical trial in patients with advanced or metastatic liver cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction with Bevazicumab (Avastin).
- Trial name
- NCT00775073
- Testing
- Everolimus, Bevacizumab
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Gerhard Treiber
Hepatocellular Carcinoma
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis and screening.Relying on the…
- Trial name
- NCT06134973
- Testing
- ultrasonic testing
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Tianjin Third Central Hospital
Advanced Liver Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced liver cancer.
- Trial name
- NCT03484962
- Testing
- Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer, cryotherapy
- Where
- 2 sites in China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma, Liver Metastases
Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer
Radiation is a standard treatment option for patients with liver cancer. Unfortunately, the tumour grows after radiation in many patients and radiation can harm normal tissues.
- Trial name
- SAVIOR (NCT04745390)
- Testing
- Radiation therapy
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatic Sarcoma
Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered
Undifferentiated embryonal sarcoma of the liver is the 3rd most common malignant liver tumor after hepatoblastoma and hepatocellular carcinoma with a peak incidence between 6 and 10 years of age.
- Trial name
- SARCOM (NCT05640960)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Recurrent Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8
Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer
This phase II trial studies the effect of stereotactic body proton radiotherapy in treating patients with liver cancer. Proton radiotherapy is a type of treatment that uses high-energy beams to treat tumors.
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04805788
- Testing
- Proton Stereotactic Body Radiation Therapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Hepatecellular Carcinoma
Affordable Made-in-India Microspheres for Liver Cancer Therapy
Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide…
- Trial name
- ReLIVE (NCT07436988)
- Testing
- 90Y-Theraspheres, 188Re-Microspheres
- Where
- 5 sites in India
- Volunteers
- 18 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis, Liver Cancer
Development of a Set of Auxiliary Decision-making System for the Perioperative Period of Hepatectomy Based on Static CT and Artificial Intelligence.
The study will prospectively recruit patients with chronic liver disease and liver cancer for static CT scans to establish a high-definition CT database.
- Trial name
- NCT07056270
- Testing
- static CT scans
- Volunteers
- 500 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for treatment of hepatocellular…
- Trial name
- NCT04721470
- Testing
- Combined therapy, Microwave ablation, Transarterial chemoembolization
- Volunteers
- 278 people
- Sponsor
- Zagazig University
Carcinoma, Hepatocellular
A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi
The 1-year and 2-year overall survival rate (OS), local control rate (FFLP), disease-free progression time (PFS), and side effects were compared in patients with hepatocellular carcinoma limited to intrahepatic unresectable…
- Trial name
- NCT03939845
- Testing
- RT, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumors, Hematologic Malignancies
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing…
- Trial name
- SPI-FOL-102 (NCT07036133)
- Testing
- Pralatrexate Injection
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.
Hepatocellular Carcinoma
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Atezolizumab plus bevacizumab is the first-line treatment for patients with advanced hepatocellular carcinoma. However, the prognosis for high-risk hepatocellular carcinoma is still poor, with a median overall survival of 7.6…
- Trial name
- NCT05886465
- Testing
- Atezolizumab, Bevacizumab, HAIC with FOLFOX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Imaging with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging) is normally used to see how tumors respond to treatment. If tumors shrink after therapy, doctors continue with the same treatment.
- Trial name
- NCT01423734
- Testing
- magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Liver Neoplasms
Anlotinib for Hepatocellular Carcinoma
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment…
- Trial name
- AFHC (NCT04954521)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
HCC - Hepatocellular Carcinoma
Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence
This study is a feasibility study about a test on adjuvant therapy for patients in hepatocellular carcinoma (HCC) with a higher risk of tumour recurrence after liver resection or ablation.
- Trial name
- NCT07839767
- Testing
- Liver-in-cube testing
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available…
- Trial name
- MORPHEUS-LIVER (NCT04524871)
- Testing
- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab
- Where
- 32 sites in United States, China and 5 more
- Volunteers
- 518 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver…
- Trial name
- HCC (NCT00877071)
- Testing
- LC Bead loaded with doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Hepatocellular Carcinoma
Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies
Background: Liver cancer is the sixth most common cancer worldwide. Diagnosing liver cancer usually requires a liver sample. Getting the best sample helps determine whether cancer is present and what kind of cancer it is.
- Trial name
- NCT04258566
- Testing
- Optical Molecular Imaging (OMI), Indocyanine Green (ICG), Electromagnetic Tracking
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.